Future investigations should include diabetic populations with PD to properly assess the efficacy profile of GLP-1 receptor agonists and determine whether the observed improvement in the MDS-UPDRS Part III score (MD = − 2.88; p = 0.01) from our analysis is reproducible in such populations. This evidence concerns the gene GLP1R and Parkinson disease.